Foundayo (Orforglipron) Oral GLP-1 Weight-Loss Treatment
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist approved by the FDA in 2026 for chronic weight management in eligible adults.

What makes Foundayo different?
Foundayo is a nonpeptide oral GLP-1 medicine taken once daily. It may be taken with or without food according to its prescribing information. It should not be combined with another GLP-1 receptor agonist.
W8MD compares Foundayo with Wegovy tablets, weekly injections and non-GLP-1 medications based on medical fit, administration preference, adverse effects, access and sustainable cost.
How W8MD can help now
Patients do not need to wait for a future drug to receive evidence-based care. W8MD can compare currently approved weight-loss medications, nutrition, sleep treatment and non-medication plans using medical history, prior attempts, preferences, coverage and sustainable cost.
Discuss currently available options with W8MD
Brooklyn: 718-946-5500 · Northeast Philadelphia: 215-676-2334
Use the form only for a non-urgent callback request. Do not submit private medical, insurance, financial or other sensitive information.
Status reviewed September 4, 2026. Recheck FDA labeling and ClinicalTrials.gov before relying on this page.

